Amgen and BIND Biosciences agreed to develop a drug for solid tumors using the latter's technology platform. The partners hope to develop a new class of drug that would be more effective and less toxic than existing chemotherapy treatments. BIND could potentially receive up to $180.5 million in upfront and milestone fees, plus royalties.

Related Summaries